The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis
Open accessAbstract
Repeat cycles of miridesap, to deplete circulating serum amyloid P component (SAP), followed by the anti-SAP antibody, dezamizumab, cleared visceral amyloid deposits in patients with systemic amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our data demonstrated that CPHPC (miridesap), developed by Pepys’ team at University College London90–92, efficiently reduces SAP concentration in serum (58.5% reduction) and bone marrow (95% reduction) in aged mice.”
From Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis (2025) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moon, J., Messroghli, D., Kellman, P., Piechnik, S. K., Robson, M. D., Ugander, M., Gatehouse, P. D., Arai, A. E., Friedrich, M. G., Neubauer, S., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-92 · Cited by 1,140
Self-citationComplement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J. M., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 797
Pepys, M. B. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 566
Self-citationTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationTherapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Richards, D. B., Cookson, L., Berges, A., Barton, S. V., Lane, T., Ritter, J., Fontana, M., Moon, J., Pinzani, M., Gillmore, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504942 · Cited by 342
Self-citationQuantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis
Banypersad, S. M., Sado, D. M., Flett, A. S., et al. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.978627 · Cited by 337
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 336
Self-citationHuman plasma fibrinogen is synthesized in the liver
Tennent, G. A., Brennan, S. O., Stangou, A. J., O'Grady, J., Hawkins, P. N., & Pepys, M. B. (2007) · Blood · doi:10.1182/blood-2006-08-040956 · Cited by 304
Self-citationAmyloid P component. A critical review
Pepys, M. B., Booth, D. R., Hutchinson, W. L., Gallimore, J. R., Collins, I. M., & Hohenester, E. (1997) · Amyloid · doi:10.3109/13506129709003838 · Cited by 181 · cited 1×
“Human serum amyloid P component (SAP) from the plasma is present in all human amyloid deposits due to its avid but reversible bind ing to amyloid fibrils of all types (4).”
BackgroundSelf-citationMilde, R., Ritter, J. M., Tennent, G. A., Loesch, A., Martínez, F. O., Gordon, S., Pepys, M. B., Verschoor, A., & Helming, L. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.065 · Cited by 162
Self-citation
Research works printed but not linked: 5
- M. A. Gertz, H. J. Landau, B. M. Weiss, Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. Am. J. Hematol. 91, E506–E508 (2016). · DOI
- V. Loustaud-Ratti, A. Cypierre, A. Rousseau, F. Yagoubi, J. Abraham, A.-L. Fauchais, P. Carrier, A. Lefebvre, D. Bordessoule, E. Vidal, D. Sautereau, A. Jaccard, Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 18, 19–24 (2011). · DOI
- P. N. Hawkins, J. P. Lavender, M. B. Pepys, Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N. Engl. J. Med. 323, 508–513 (1990). · DOI
- D. F. Hutt, T. Lane, J. D. Gillmore, H. J. Lachmann, S. D. J. Gibbs, P. T. Sattianayagam, D. Gopaul, A. M. Quigley, P. N. Hawkins, A. D. Wechalekar, Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis. Amyloid 17 (suppl. 1), 57 (2010).
- D. F. Hutt, A.-M. Quigley, J. Page, M. L. Hall, M. Burniston, D. Gopaul, T. Lane, C. J. Whelan, H. J. Lachmann, J. D. Gillmore, P. N. Hawkins, A. D. Wechalekar, Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur. Heart J. Cardiovasc. Imaging 15, 1289–1298 (2014). · DOI
Cited by
Sorted by citations
Items 101–121 of 121
From pathophysiology to treatment in transthyretin cardiac amyloidosis.
Correia-Rodrigues, Â., Ribeiro-Rodrigues, T. M., Gonçalves, L., Almeida, J., Ferreira, M. J., & Girão, H. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.002 · Cited by 1
Nonspecific Interaction of Immunoglobulins (IgG) with Human Beta-2 Microglobulin Fibrils
Polyakov, D., Grudinina, N. A., Antimonova, O., Klysbaeva, L. I., Sakhabeev, R., & Shavlovsky, M. (2025) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093025010120 · Cited by 1
“The works have come out recently [15, 16], including those of the clinical profile, indicative of the prospect of immunological approach based on amyloid degradation under the action of specific antibodies to its components [17–20].”
Antibodies to Congo Red Dye as a Promising Tool for Detection and Destruction of Amyloid
Antimonova, O., Polyakov, D., Grudinina, N. A., Masterova, K. V., & Shavlovsky, M. (2024) · Cell and Tissue Biology · doi:10.1134/s1990519x24700639 · Cited by 1
“…approach has been described in the literature and involves administration of antibodies to serum amyloid P (SAP), which is known to be an obligatory component of all types of amyloid, regardless of the nosological entity (Richards et al., 2015, 2018), to patients suffering from amyloidosis.”
Ma, J.-H., Liu, Q., & White, J. R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101136 · Cited by 1
“(2021) 297(4) 101136 10 mM MES buffer, pH 6.”
BackgroundMethodInfluentialMystery in the mediastinum: Rare case of indolent primary thoracic amyloids
Munagala, R., Mishra, P., Lodh, A., Shukla, D., Bhatt, A. N., Taskar, V., & Keshavamurthy, J. (2021) · Lung India · doi:10.4103/lungindia.lungindia_916_20 · Cited by 1
“Some SAP is left in amyloid deposits, which serves as a target for Dezamizumab, an anti-SAP antibody that specifically allows for amyloid clearance.[9] Despite the advancements, no curative treatment for amyloidosis exists.”
BackgroundWITHDRAWN: [Treatment of AL amyloidosis].
Jaccard, A., & Bridoux, F. (2019) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2019.03.002 · Cited by 1
Prognose und Therapie der AL-Amyloidose
Hansen, T. (2019) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-019-6380-9 · Cited by 1
Ghosh, S., Khanra, D., Kala, C., Krishna, V., & Thakur, A. (2025) · Journal of Association of Physicians of India · doi:10.59556/japi.73.1050
Transthyretin amyloidosis. Fundamentals of pathogenesis, diagnosis, treatment, prognosis
Shavlovsky, M., Gudkova, A., Krutikov, A. N., & Antimonova, O. (2024) · Medical academic journal · doi:10.17816/maj625774
Karam, S., Kaushal, A., Amer, N. A., Royal, V., & Kitchlu, A. (2024) · Advances in kidney disease and health · doi:10.1053/j.akdh.2024.02.001
Advances in understanding, diagnosis and targeting ATTR cardiomyopathy: a review
Kulak, M., Lang, M., Waśniewski, M., & Lange, N. (2024) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/189121
“A subsequent phase 2 clinical trial failed to show a positive effect on cardiac amyloid deposits with ATTR-CA, and further studies of Miridesap were aban - doned [99].”
BackgroundKappa chain amyloidosis: a deadly entity not to forget in patients with nondiabetic proteinuria
Abrantes, A., Luz, I., Santos, P. A., Barreto, P., Ferrer, F., & Lobos, A. (2022) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.20.04539-8
Losa, M., Schürch, P., Carta, M. C., Morales, I. C., Frontzek, K., Lysenko, V., Lakkaraju, A. K. K., Delic, M., Schwarz, P., Westermark, G., et al. (2021) · bioRxiv · doi:10.1101/2021.05.01.442282
Nanoparticles targeting amyloid deposits: a potential contrast agent for diagnosis and treatment
Tepper, M., Eravuchira, P., Gabay, B., Sharabani‐Yosef, O., & Gannot, I. (2021) · Journal of Nanophotonics · doi:10.1117/1.jnp.15.026010
“Only two drugs for amyloid removal are currently in clinical trials.(8,9) However, these drugs are based on immunotherapy, which is very expensive, and have not advanced yet to phase 3 clinical trials.”
BackgroundKrauth, M., & Agis, H. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00689-2
“patients with cardiac involvement [36].”
DUAL expectations in light chain amyloidosis
Schönland, S., & Palladini, G. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100461
“Despite a favorable phase Ia/Ib trial [8], a phase II study was terminated early due to changes in risks/benefits profile [9].”
BackgroundRech, J.-S., Brillet, P., Jeny, F., Kambouchner, M., Nunes, H., Arnulf, B., Valeyre, D., & Uzunhan, Y. (2019) · Pulmonary Manifestations of Systemic Diseases · doi:10.1183/2312508x.10021719
The Clinical Spectrum of Amyloidosis
Reddy, A., Ballesteros, E., & Harrison, J. S. (2018) · Amyloid Diseases · doi:10.5772/intechopen.82763
“A recent phase Ib trial of SAP inhibitor, Miridesap followed by humanized monoclonal antibody Dezamizumab against SAP showed clearance of amyloid fibrils in liver and spleen, confirmed by I-SAP scintigraphy [19].”
Systemic light chain amyloidosis
Sinnakirouchenan, R. (2020) · Onco-Nephrology · doi:10.1016/b978-0-323-54945-5.00017-5
Averyanov, A., Kogan, E., Lesnyak, V., & Stepanyan, I. (2020) · Difficult to Diagnose Rare Diffuse Lung Disease · doi:10.1016/b978-0-12-815375-8.00005-4
Sud, R., & Pavendranathan, G. (2019) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.65654-4
Metadata
- Authors
- Richards, D. B., Cookson, L. M., Barton, S. V., Liefaard, L., Lane, T., Hutt, D. F., Ritter, J. M., Fontana, M., Moon, J. C., Gillmore, J. D., Wechalekar, A., Hawkins, P. N., & Pepys, M. B.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- National Health Service (GB)
- Guy's Hospital (GB)
- St Bartholomew's Hospital (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-01-03
- Volume
- 10
- Issue
- 422
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2782423765
- Cited by
- 136
- References
- 0
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 18 · 2023: 8 · 2022: 21 · 2021: 20 · 2020: 20 · 2019: 20 · 2018: 13
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- GlaxoSmithKline (award308029, N/A)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- systemic amyloidosis, cardiac amyloidosis, serum amyloid P component, anti-amyloid antibodies, amyloid deposition, spleen, kidney, antibody therapy
- MeSH terms
- Serum Amyloid P-Component, Amyloidosis, Antibodies, Humans, Magnetic Resonance Imaging, Radionuclide Imaging, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
